Grail (GRAL) shares were over 44% lower in recent Friday premarket activity, a day after the company said its NHS-Galleri trial missed its primary Stage III and IV cancer reduction endpoint.
Akamai Technologies (AKAM) stock was down nearly 11% after the company issued overnight lower-than-expected Q1 and 2026 non-GAAP earnings guidance.
Chemours (CC) stock was down more than 9%, a day after the company posted lower Q4 adjusted EPS and sales.
Hudbay Minerals (HBM) shares were 3% lower after the company reported lower-than-expected Q4 adjusted EPS and revenue.